Rep. April McClain Delaney Purchases BWX Technologies, Inc. (NYSE:BWXT) Stock

Representative April McClain Delaney (Democratic-Maryland) recently bought shares of BWX Technologies, Inc. (NYSE:BWXT). In a filing disclosed on August 03rd, the Representative disclosed that they had bought between $1,001 and $15,000 in BWX Technologies stock on July 27th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Life Time Group (NYSE:LTH) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Liberty Media Corporation – Liberty Formula One Series C (NASDAQ:FWONK) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of C.H. Robinson Worldwide (NASDAQ:CHRW) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Somnigroup International (NYSE:SGI) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Life Time Group (NYSE:LTH) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Service Corporation International (NYSE:SCI) on 7/30/2026.

BWX Technologies Stock Down 2.2%

Shares of BWX Technologies stock opened at $168.65 on Thursday. The company has a 50-day simple moving average of $186.21 and a two-hundred day simple moving average of $200.99. The stock has a market capitalization of $15.45 billion, a PE ratio of 43.69, a price-to-earnings-growth ratio of 2.85 and a beta of 0.76. BWX Technologies, Inc. has a 52-week low of $157.10 and a 52-week high of $241.82. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.33 and a current ratio of 2.40.

BWX Technologies (NYSE:BWXT) last posted its quarterly earnings results on Monday, August 3rd. The technology company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.03. The firm had revenue of $901.62 million for the quarter, compared to analysts’ expectations of $902.41 million. BWX Technologies had a net margin of 10.11% and a return on equity of 30.83%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.02 earnings per share. BWX Technologies has set its FY 2026 guidance at 4.700-4.800 EPS. On average, analysts anticipate that BWX Technologies, Inc. will post 4.74 EPS for the current fiscal year.

BWX Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 4th. Shareholders of record on Tuesday, August 18th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $1.08 annualized dividend and a yield of 0.6%. BWX Technologies’s payout ratio is 27.98%.

Institutional Investors Weigh In On BWX Technologies

Large investors have recently made changes to their positions in the company. WFA of San Diego LLC purchased a new position in shares of BWX Technologies in the second quarter worth approximately $29,000. MV Capital Management Inc. purchased a new position in shares of BWX Technologies during the 4th quarter valued at about $32,000. Tucker Asset Management LLC bought a new position in shares of BWX Technologies during the 4th quarter valued at approximately $36,000. Vermillion Wealth Management Inc. increased its holdings in BWX Technologies by 71.7% in the 4th quarter. Vermillion Wealth Management Inc. now owns 237 shares of the technology company’s stock worth $41,000 after acquiring an additional 99 shares in the last quarter. Finally, Smithfield Trust Co increased its holdings in BWX Technologies by 52.1% in the 4th quarter. Smithfield Trust Co now owns 251 shares of the technology company’s stock worth $44,000 after acquiring an additional 86 shares in the last quarter. 94.39% of the stock is currently owned by institutional investors.

Key BWX Technologies News

Here are the key news stories impacting BWX Technologies this week:

• Positive Sentiment: BWXT agreed to sell its medical isotopes business to Nordic Capital for up to $800 million. The divestiture should provide liquidity for investment in nuclear-energy, small modular reactor and defense capacity, while allowing the company to focus on its core businesses. BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
• Positive Sentiment: Second-quarter results exceeded expectations, with adjusted EPS of $1.07 versus the $1.04 consensus and revenue of approximately $901.6 million, up 18% year over year. Commercial operations revenue increased 72% to $302.5 million, while backlog expanded to roughly $8.39 billion. BWXT Q2 Earnings Call Centers on Higher Outlook and Nuclear Focus
• Positive Sentiment: Management raised 2026 adjusted EPS guidance to $4.70–$4.80 and free-cash-flow guidance to $345 million–$360 million. The company also recently completed its Precision Components Group acquisition, expanding manufacturing capabilities for commercial nuclear components. BWXT Raises EPS and Free Cash Flow Outlook
• Positive Sentiment: BTIG reaffirmed its Buy rating and maintained a $235 price target. Northland Securities modestly increased its FY2026 EPS estimate to $4.71 and FY2027 estimate to $5.17, signaling confidence in longer-term earnings growth.
• Neutral Sentiment: BWXT maintained its quarterly dividend at $0.27 per share, payable September 4, although the approximately 0.6% yield is unlikely to be a major near-term share-price catalyst.
• Negative Sentiment: Northland lowered its Q3 2026 EPS estimate to $1.18 from $1.22, potentially contributing to pressure on near-term earnings expectations. BWXT also trades at a relatively high valuation, while regulatory delays, long SMR deployment timelines and integration or capacity-expansion costs remain risks.

Insider Activity at BWX Technologies

In other news, CEO Rex D. Geveden sold 10,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $204.81, for a total value of $2,048,100.00. Following the completion of the transaction, the chief executive officer owned 202,491 shares of the company’s stock, valued at $41,472,181.71. This represents a 4.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Thomas Fitzgerald sold 2,417 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $209.25, for a total value of $505,757.25. Following the sale, the chief financial officer owned 6,884 shares of the company’s stock, valued at $1,440,477. This represents a 25.99% decrease in their position. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BWXT has been the topic of several recent analyst reports. Truist Financial increased their target price on BWX Technologies from $205.00 to $212.00 and gave the company a “hold” rating in a research note on Monday, May 11th. Wall Street Zen raised BWX Technologies from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Deutsche Bank Aktiengesellschaft upgraded BWX Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $205.00 to $255.00 in a report on Friday, May 15th. Weiss Ratings lowered BWX Technologies from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. assumed coverage on shares of BWX Technologies in a report on Monday, July 27th. They set an “overweight” rating and a $230.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.20.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.